Takeda Pharmaceutical sells assets to Hypera S.A. for $825M

Takeda Pharmaceutical Company has announced the sale of a portfolio of prescription and over the counter products to Brazil's Hypera S.A. in a deal worth $825M.



“Takeda remains firmly committed to the emerging markets and Latin America. This divestment enables us to focus on our investments in these countries that centre on our highly innovative medicines across Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience."
Ricardo Marek, President, Takeda Growth & Emerging Markets Business Unit

The announcement comes as part of a broader plan to divest non-core assets worth an estimated $10B in an effort to reduce leverage.

The_MergerSight_Group_Instagram
The_MergerSight_Group_LinkedIn
The_MergerSight_Group_Facebook

© 2018 - 2020 The MergerSight Group

Subscribe to Newsletter